Copyright
©The Author(s) 2021. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Gastroenterol. Mar 21, 2021; 27(11): 1006-1021
Published online Mar 21, 2021. doi: 10.3748/wjg.v27.i11.1006
Published online Mar 21, 2021. doi: 10.3748/wjg.v27.i11.1006
Genotype 3-hepatitis C virus’ last line of defense
Dorota Zarębska-Michaluk, Department of Infectious Diseases, Jan Kochanowski University, Kielce 25-369, Świętokrzyskie, Poland
Author contributions: Zarębska-Michaluk D contributed to the manuscript.
Conflict-of-interest statement: No conflict of interest.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Dorota Zarębska-Michaluk, Professor, Department of Infectious Diseases, Jan Kochanowski University, Żeromskiego 5, Kielce 25-369, Świętokrzyskie, Poland. dorota1010@tlen.pl
Received: January 11, 2021
Peer-review started: January 11, 2021
First decision: January 23, 2021
Revised: January 24, 2021
Accepted: February 28, 2021
Article in press: February 28, 2021
Published online: March 21, 2021
Peer-review started: January 11, 2021
First decision: January 23, 2021
Revised: January 24, 2021
Accepted: February 28, 2021
Article in press: February 28, 2021
Published online: March 21, 2021
Core Tip
Core Tip: Genotype 3 which is second in frequency worldwide, is unique among genotypes of hepatitis C virus in its higher rate of steatosis, accelerated fibrosis progression, and lower cure rates. This paper describes the genotype-specific mechanisms of liver injury and provides an overview of therapeutic options. Currently, available highly potent pangenotypic regimens have revolutionized the treatment of genotype 3 infection, however, patients with liver cirrhosis and those who fail to response to direct-acting antiviral therapy still present a therapeutic challenge.